Page 54 - 2019秋季手冊內頁-ebook測試
P. 54
7. 『國家新創獎』 2019.
“開發新穎 R-脊椎蛋白 3 (R-Spondin 3) 單株抗體候選藥物 DBPR117: 鎖定由
RSPO3/Wnt 誘發腫瘤生成之精準藥物”
MAJOR ACHIEVEMENTS:
• DBPR112, IND approval and phase I clinical trial, project leader.
• DBPR114, IND approval by USFDA and TFDA in 2017, team member.
• 於美國 Merck & Co.期間所參與之 Zostavax® and ProQuad®開發計畫分別於 2005、
2006 年，通過美國 FDA 審核上市。
• More than 100 publications in peer reviewed journals in areas of antibody engineering
and drug discovery for anti-viral (HCV, influenza, and EV71) and anti-cancer indications.
55
